Effects of interferon-alpha on a reduced release of interleukin-8 from latently HIV-1-infected monocytic cell line U937 cells.
The effects of human interferon-alpha (IFN-alpha) on the release of an antimicrobial interleukin, interleukin-8 (IL-8), from human immunodeficiency virus type 1 (HIV-1)-infected myelomonocytic cell line, U937, were studied in vitro to evaluate the potential of IFN-alpha in the management of acquired immunodeficiency syndrome (AIDS)-associated opportunistic diseases. The latently HIV-1-infected U937 cells (U937/HIV-1(L)) showed a marked reduction of IL-8 secretion as compared to uninfected U937 cells, whereas IL-8 release from productively HIV-1-infected U937 cells was comparable to uninfected cells. The IFN-alpha recovered partially the reduced IL-8 level from U937/HIV-1(L) cells in a dose-dependent manner. Any significant inhibition of IFN-alpha-augmented IL-8 secrement by anti-IL-1 antibody was not observed, suggesting that the enhanced IL-8 secretion occurred without augmenting IL-1 production. The IFN-alpha-augmented IL-8 secretion from latently HIV-1-infected U937 cells may suggest a beneficial potential of IFN-alpha in a treatment of bacterial or fungal infection frequently seen in patients with progressive stages of HIV-1 infection.
Ohashi
K
K
Fujisaki Institute, Hayashibara Biochemical Labs., Inc., Okayama, Japan.
Akazawa
R
R
Kurimoto
M
M
D000163:Acquired Immunodeficiency Syndrome / Q000097:blood / Q000188:drug therapy*; D005069:Evaluation Studies as Topic; D006801:Humans; D016898:Interferon-alpha / Q000494:pharmacology*; D016209:Interleukin-8 / Q000097:blood*; D009000:Monocytes / Q000187:drug effects* / Q000378:metabolism; D014407:Tumor Cells, Cultured; D017735:Virus Latency
D016898:Interferon-alpha; D016209:Interleukin-8